Guillaume Pfefer heads up Kala Pharma
This article was originally published in Scrip
Kala Pharmaceuticals, a developer of products that penetrate the mucosal barrier to treat a wide range of diseases, has appointed Dr Guillaume Pfefer president and CEO and a member of the board of directors. Prior to joining Kala, Dr Pfefer served nine years at Sanofi Pasteur, most recently as general manager of Sanofi Pasteur Mexico.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.